hema.to secures funding for blood diagnostics

hema.to develops a cloud-based platform that uses artificial intelligence to accelerate the diagnosis of blood cancer and immune diseases

Landshut/Munich, February 27, 2025 - Munich-based deeptech startup hema.to has successfully closed a financing round led by LUMO Labs. Investors include Bayern Kapital, the venture and growth capital company of the Free State of Bavaria, as well as Cross Atlantic Angels and several existing backers, including Elaia, Heal Capital, High-Tech Gründerfonds (HTGF) and Becker Ventures. With the new capital raise, hema.to plans to further develop its AI-supported diagnostic solution and scale it for the market.

AI-supported cytometry to relieve the burden on clinical laboratories

The diagnosis of blood cancer and immune disorders is a complex process that has so far been carried out manually by specialists in clinical laboratories. The analysis can take an average of 20 minutes per sample. At the same time, the pressure on laboratories is increasing due to a shortage of specialists and high case numbers.

Our goal is to bring AI-supported precision diagnostics to immunomedicine, relieve the burden on laboratory staff and enable customized treatment for patients

Karsten Miermans, CEO and co-founder of hema.to

This is where hema.to comes in with an AI-supported analysis platform. The cloud-based solution evaluates raw cytometry data within seconds and recognizes disease-specific patterns. The aim: faster, more precise and earlier diagnosis of blood cancer and other diseases.

Reduced analysis time and improved diagnostic reliability

By using the hema.to platform, the duration of the blood sample analysis can be reduced to around one minute. The solution also reduces the probability of false-negative diagnoses for secondary pathologies by a factor of ten. The combination of automated AI analysis and technical validation by laboratory experts should ensure optimized diagnostic reliability.

Use in laboratories and future expansion

The hema.to platform is already being used in the first clinical laboratories and hospitals. In future, the system is to be extended to other autoimmune diseases as well as applications in clinical trials and therapy monitoring.

The workload in clinical laboratories is high, and in the case of life-threatening diseases such as leukemia or lymphoma, a quick and precise diagnosis can be crucial

Monika Steger, Managing Director of Bayern Kapital

Bayern Kapital's support underlines the importance of innovative medical technology solutions.

LUMO Labs also sees the AI-supported platform as a significant step forward for precision medicine: "Our investments in digital health and medtech are aimed at improving the quality of life of patients and medical professionals," says Sven Bakkes, Partner at LUMO Labs. "hema.to not only speeds up the analysis process considerably, but can also help to detect diseases at an early stage."